Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury

H Susana Marinho, Paulo Marcelino, Helena Soares, M Luisa Corvo

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been identified. Gene silencing through RNA interference (RNAi) by means of small interference RNA (siRNA) targeting mediators of IRI is a promising therapeutic approach.

OBJECTIVE: This study aims at reviewing the use of siRNAs as therapeutic agents to prevent IRI during liver transplantation.

METHOD: We review the crucial choice of siRNA targets and the advantages and problems of the use of siRNAs.

RESULTS: We propose possible targets for siRNA therapy during liver IRI. Moreover, we discuss how drug delivery systems, namely liposomes, may improve siRNA therapy by increasing siRNA stability in vivo and avoiding siRNA off-target effects.

CONCLUSION: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies.

Original languageEnglish
JournalCurrent Pharmaceutical Design
DOIs
Publication statusE-pub ahead of print - 7 Aug 2018

Fingerprint

Gene Silencing
RNA Interference
Reperfusion Injury
Liver
Therapeutics
RNA Stability
Organ Transplantation
Drug Delivery Systems
Liposomes
Liver Transplantation
Ischemia
Inflammation

Cite this

@article{ed72fd30568847eab22567db8eaea542,
title = "Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury",
abstract = "BACKGROUND: Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been identified. Gene silencing through RNA interference (RNAi) by means of small interference RNA (siRNA) targeting mediators of IRI is a promising therapeutic approach.OBJECTIVE: This study aims at reviewing the use of siRNAs as therapeutic agents to prevent IRI during liver transplantation.METHOD: We review the crucial choice of siRNA targets and the advantages and problems of the use of siRNAs.RESULTS: We propose possible targets for siRNA therapy during liver IRI. Moreover, we discuss how drug delivery systems, namely liposomes, may improve siRNA therapy by increasing siRNA stability in vivo and avoiding siRNA off-target effects.CONCLUSION: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies.",
author = "Marinho, {H Susana} and Paulo Marcelino and Helena Soares and Corvo, {M Luisa}",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2018",
month = "8",
day = "7",
doi = "10.2174/1381612824666180807124356",
language = "English",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "BENTHAM SCIENCE PUBL LTD",

}

Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury. / Marinho, H Susana; Marcelino, Paulo; Soares, Helena; Corvo, M Luisa.

In: Current Pharmaceutical Design, 07.08.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury

AU - Marinho, H Susana

AU - Marcelino, Paulo

AU - Soares, Helena

AU - Corvo, M Luisa

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2018/8/7

Y1 - 2018/8/7

N2 - BACKGROUND: Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been identified. Gene silencing through RNA interference (RNAi) by means of small interference RNA (siRNA) targeting mediators of IRI is a promising therapeutic approach.OBJECTIVE: This study aims at reviewing the use of siRNAs as therapeutic agents to prevent IRI during liver transplantation.METHOD: We review the crucial choice of siRNA targets and the advantages and problems of the use of siRNAs.RESULTS: We propose possible targets for siRNA therapy during liver IRI. Moreover, we discuss how drug delivery systems, namely liposomes, may improve siRNA therapy by increasing siRNA stability in vivo and avoiding siRNA off-target effects.CONCLUSION: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies.

AB - BACKGROUND: Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been identified. Gene silencing through RNA interference (RNAi) by means of small interference RNA (siRNA) targeting mediators of IRI is a promising therapeutic approach.OBJECTIVE: This study aims at reviewing the use of siRNAs as therapeutic agents to prevent IRI during liver transplantation.METHOD: We review the crucial choice of siRNA targets and the advantages and problems of the use of siRNAs.RESULTS: We propose possible targets for siRNA therapy during liver IRI. Moreover, we discuss how drug delivery systems, namely liposomes, may improve siRNA therapy by increasing siRNA stability in vivo and avoiding siRNA off-target effects.CONCLUSION: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies.

U2 - 10.2174/1381612824666180807124356

DO - 10.2174/1381612824666180807124356

M3 - Article

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

ER -